Health Media Articles
Below are key excerpts of revealing news articles on health from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.
For further exploration, delve into our comprehensive Health and Food Corruption Information Center.
A new EWG peer-reviewed study has found chlormequat, a little-known pesticide, in four out of five, or 80 percent, of people tested. The groundbreaking analysis of chlormequat in the bodies of people in the U.S. rings alarm bells, because the chemical is linked to reproductive and developmental problems in animal studies, suggesting the potential for similar harm to humans. EWG’s research, published February 15 in the Journal of Exposure Science and Environmental Epidemiology, tested for the presence of chlormequat in urine collected from 96 people between 2017 and 2023. The chemical was found in the urine of 77 of them. We detected the chemical in 92 percent of oat-based foods purchased in May 2023, including Quaker Oats and Cheerios. The fact that so many people are exposed raises concerns about its potential impact on public health, since animal studies link chlormequat to reduced fertility, harm to the reproductive system and altered fetal growth. Environmental Protection Agency regulations allow the chemical to be used on ornamental plants only – not food crops – grown in the U.S. But its use is permitted on imported oats and other foods sold here. Many oats and oat products consumed in the U.S. come from Canada. Chlormequat was not allowed on oats sold in the U.S. before 2018, when the Trump EPA gave first-time approval for some amount of the chemical on imported oats. The same administration in 2020 increased the allowable level.
A US court this week banned three weedkillers widely used in American agriculture, finding that the Environmental Protection Agency (EPA) broke the law in allowing them to be on the market. The ruling is specific to three dicamba-based weedkillers manufactured by Bayer, BASF and Syngenta, which have been blamed for millions of acres of crop damage and harm to endangered species and natural areas across the midwest and south. Discovery documents turned up in the litigation showed the companies knew that their dicamba weedkillers would probably lead to off-target crop damage. This is the second time a federal court has banned these weedkillers since they were introduced for the 2017 growing season. In 2020, the ninth circuit court of appeals issued its own ban, but months later the Trump administration reapproved the weedkilling products. But a federal judge in Arizona ruled on Monday that the EPA made a crucial error in reapproving dicamba, finding the agency did not post it for public notice and comment as required by law. US district judge David Bury wrote ... that it was a “very serious” violation and that if EPA had done a full analysis, it probably would not have made the same decision. Bury wrote that the EPA did not allow many people who are deeply affected by the weedkiller – including specialty farmers, conservation groups and more – to comment. “The evidence has shown that dicamba cannot be used without causing massive and unprecedented harm to farms as well as endangering plants and pollinators,” said George Kimbrell [with] the Center for Food Safety, which litigated the case.
An advertising agency that helped market the blockbuster painkiller OxyContin will pay $350 million to states ravaged by the nation’s opioid crisis. Attorneys general from multiple states alleged that Publicis Health developed “unfair and deceptive” marketing campaigns aimed at persuading doctors to prescribe the addictive drug for longer periods of time and at higher doses. The company’s client was Purdue Pharma, the Connecticut drugmaker accused in lawsuits of helping ignite the epidemic through aggressive marketing and sales of OxyContin. Publicis, a subsidiary of French ad giant Publicis Groupe, settled with 50 states and D.C. Under the agreements, Publicis Health will stop accepting work related to prescription opioids and must release thousands of internal documents chronicling its dealings with companies such as Purdue. It is the first settlement with an advertising agency connected to the opioid crisis, according to the New York attorney general’s office. “Publicis was responsible for creating advertisements and materials, such as pamphlets and brochures that promoted OxyContin as safe and unable to be abused, even though this claim was not true,” according to a news release from the office of New York Attorney General Letitia James. Drug overdoses killed nearly 110,000 people in the United States in 2022, a record high, according to federal death statistics.
Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.
Mental health apps have become increasingly common over the past few years, particularly due to the rise in telehealth during the coronavirus pandemic. However, there's a problem: Data privacy is being compromised in the process. In 2023 the Federal Trade Commission ordered the mental health platform BetterHelp, which is owned by Teladoc (TDOC), to pay a $7.8 million fine to consumers for sharing their mental health data for advertising purposes with Facebook (META) and Snapchat (SNAP) after previously promising to keep the information private. Cerebral, a telehealth startup, admitted last year to exposing sensitive patient information to companies like Google (GOOG, GOOGL), Meta, TikTok, and other third-party advertisers. This info included patient names, birth dates, insurance information, and the patient's responses to mental health self-evaluations through the app. Overall, according to the Mozilla Foundation’s Privacy Not Included online buyer’s guide, only two out of the 27 mental health apps available to users met Mozilla's privacy and security standards in 2023. A December 2022 study of 578 mental health apps published in the Journal of the American Medical Association found that 44% shared data they collected with third parties. A February 2023 report from Duke University found that out of 37 different data brokers that researchers contacted ... firms “were ultimately willing and able to sell the requested mental health data.”
Researchers have long known that any single antidepressant drug is little more effective than a placebo in the majority of trials, shown to be less effective than a placebo in some studies, and generally found to be “clinically negligible” with respect to depression remission, while often resulting in severe adverse effects; for example, resulting in a higher percentage of sexual dysfunction than depression remission. However, for nearly twenty years, psychiatry and Big Pharma have told us that while one antidepressant may not work for the majority of patients, in the “real world,” doctors provide patients who have been failed by their initial antidepressant with another antidepressant, and if that fails, still another; and that this real-world treatment is successful for nearly 70% of patients. The problem with this “nearly 70%” story is that the research that has been used to justify it, a 2006 report on the results of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D), has long been disputed by researchers. Moreover, a recent reanalysis of previously undisclosed data reveals that STAR*D, owing to scientific misconduct that dramatically inflated remission rates, may go down in US medical history as one of its most harmful scandals. Even [STAR*D's] fabricated 67% depression remission rate should never have been celebrated. 85% of depressed individuals who go without somatic treatments spontaneously recover within 1 year.
Note: Read more important news articles we've summarized on medical and scientific corruption regarding antidepressants. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.
By contributing to the development of chronic disease and death, a group of hormone-disruptive plastic chemicals is costing the US health care system billions — over $249 billion in 2018 alone, a new study found. The new research analyzed the impact of four groups of chemicals used in the production of plastic products: Flame retardants called polybrominated diphenyl ethers, or PBDE; phthalates, which are used to make plastic more durable; bisphenols such as BPA and BPS used to create hard plastics and resins; and per- and polyfluoroalkyl substances, also known as PFAS. However, these are just a fraction of the chemicals used to make plastics. A United Nations report published in May found more than 13,000 chemicals are used in plastics production. The four chemicals measured in the new study ... are thought to interfere with the body’s mechanism for hormone production, known as the endocrine system, and cause damage to developmental, reproductive, immune and cognitive systems. “The biggest impact of endocrine-disrupting chemicals is on children’s brain development because they disrupt thyroid hormones in pregnancy,” [lead author Dr. Leonardo] Trasande said. The report recommended blood tests for people at high risk such as firefighters, workers in fluorochemical manufacturing plants, and those who live near commercial airports, military bases, landfills, incinerators, wastewater treatment plants and farms.
Common consumer products may contain hundreds of chemicals that could increase our risk of developing breast cancer, scientists have warned. While some chemicals are known to directly cause cancer, many others indirectly promote the cancer by increasing our susceptibility to the establishment and growth of certain tumors. Breast cancer occurs when cells in the breast tissue grow out of control. Among the many risk factors associated with this disease is over-exposure to estrogen, progesterone and hormonal disruption. And it's not just hormonal contraception that can influence our body's hormone levels; numerous synthetic chemicals have been shown to disrupt our hormones, with potential impacts on our risk of developing various diseases. "Breast cancer is a hormonal disease, so the fact that so many chemicals can alter estrogen and progesterone is concerning," Jennifer Kay, a research scientist at Silent Spring Institute, said. In a new study, published in the journal Environmental Health Perspectives, Kay and colleagues searched through multiple international and U.S. government databases to identify chemicals that had been found to cause mammary tumors in animals. In total, the team identified 921 chemicals that could potentially promote the development of breast cancer, 90 percent—or 829—of which are commonly included in consumer products, food, drinks, pesticides, medications and workplaces.
Sixty percent of US physicians serving as panel and task force members for the American Psychiatric Association’s official manual of psychiatric disorders received payments from industry totalling $14.24m, finds a study published by The BMJ. Because of the enormous influence of diagnostic and treatment guidelines, the researchers say their findings “raise questions about the editorial independence of this diagnostic manual.” Often referred to as the ‘bible’ of psychiatric disorders, the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, text revision (DSM-5-TR) is the latest edition of the guide that doctors use to diagnose and treat patients. It is thus critical that authors of this psychiatric taxonomy should be free of industry ties. But until the development of Open Payments ... it wasn't possible to determine the amount of monies received by authors of diagnostic and clinical practice guidelines. Their analysis included 92 physicians based in the US who served as members of either a panel (86) or task force (6) on the DSM-5-TR from 2016-19. Of these 92 individuals, 55 (60%) received payments from industry. Collectively, these panel members received a total of $14.24m (£11.21m; €12.96m). The most common types of payment were for food and beverages (91%), followed by travel (69%) and consulting (69%). The greatest proportion of compensation by category of payment was for research funding (70%). To ensure unbiased, evidence based mental health practice, there should be a rebuttable presumption of prohibiting financial conflicts of interest among the panel and task force members.
Note: A recent study found that 80% of the global population will be treated for mental illness at some point in their lives, and that their lives are worse in many ways after receiving diagnosis and treatment. For more along these lines, see concise summaries of deeply revealing news articles on health and Big Pharma profiteering from reliable major media sources.
Researchers have discovered bottled water sold in stores can contain 10 to 100 times more bits of plastic than previously estimated — nanoparticles so infinitesimally tiny they cannot be seen under a microscope. At 1,000th the average width of a human hair, nanoplastics are so teeny they can migrate through the tissues of the digestive tract or lungs into the bloodstream, distributing potentially harmful synthetic chemicals throughout the body and into cells. One liter of water — the equivalent of two standard-size bottled waters — contained an average of 240,000 plastic particles from seven types of plastics, of which 90% were identified as nanoplastics and the rest were microplastics. Microplastics are polymer fragments that can range from less than 0.2 inch (5 millimeters) down to 1/25,000th of an inch (1 micrometer). Anything smaller is a nanoplastic that must be measured in billionths of a meter. The new finding reinforces long-held expert advice to drink tap water from glass or stainless steel containers to reduce exposure. In the new study, published ... in the journal Proceedings of the National Academy of Sciences, researchers from Columbia University presented a new technology that can see, count and analyze the chemical structure of nanoparticles in bottled water. Nanoplastics ... can invade individual cells and tissues in major organs, potentially interrupting cellular processes and depositing endocrine-disrupting chemicals.
Note: For more along these lines, see concise summaries of deeply revealing news articles on health from reliable major media sources.
Sidney M. Wolfe, an American physician turned activist who relentlessly lobbied against drug companies and the US Food and Drug Administration, died on Monday in his Washington home. He was 86. Wolfe ... co-founded the Public Citizen’s Health Research Group, which “promotes research-based, system-wide changes in health-care policy and drug safety,” according to the group’s website. He also served as the director and senior adviser of the non-profit, where he crusaded against FDA rulings on more than two dozen dangerous or ineffective drugs until they were yanked off the market. In an op-ed published in HuffPost in 2011, Wolfe ridiculed the FDA for being “cautious on food safety — reckless on prescription drug safety.” The banned medicines include the diabetes drug phenformin, which was linked to hundreds of deaths and sold under the trade names DBI and Meltrol in the US for 20 years. Wolfe was also responsible for the banning of the anti-inflammatory Vioxx ... which he warned caused serious heart damage years before it was taken off the market — as well as the anti-diarrheal alosetron. His group also successfully petitioned federal regulators to include a warning on aspirin bottles about Reye’s syndrome, a rare but potentially fatal condition that causes swelling in the liver and brain. In addition, Wolfe was a fierce foe of silicone gel-filled breast implants for breast augmentation and reconstruction surgeries, claiming in the 1980s that they cause cancer.
Note: Read the full remembrance of Dr. Sidney Wolfe’s legacy. His leadership helped remove 28 dangerous medications off the market, and paved the way for “vital and path-breaking research and advocacy on doctor discipline, mental health, tobacco, pharmaceutical marketing, drug company payments to doctors, medical devices, health insurance and the imperative of Medicare for All, unnecessary Cesarean sections, unregulated supplements, medical resident work hours, and more.” For more along these lines, see concise summaries of deeply revealing news articles on health and Big Pharma corruption from reliable major media sources.
Poison control centers across the US say they are seeing a steep increase in calls related to semaglutide, an injected medication used for diabetes and weight loss, with some people reporting symptoms related to accidental overdoses. Some have even needed to be hospitalized for severe nausea, vomiting and stomach pain, but their cases seem to have resolved after they were given intravenous fluids and medications to control nausea. From January through November, the America’s Poison Centers reports nearly 3,000 calls involving semaglutide, an increase of more than 15-fold since 2019. In 94% of calls, this medication was the only substance reported. In most of the calls, people reported dosing errors, said Dr. Kait Brown, clinical managing director of the association. “Oftentimes, it’s a person who maybe accidentally took a double dose or took the wrong dose,” Brown said. Semaglutide was approved by the US Food and Drug Administration in 2017. It is sold as Ozempic when used for diabetes and Wegovy when used for weight loss. Even when used as directed by a doctor, people can have stomach and bowel side effects, including nausea, vomiting and constipation, especially when they start the drugs. After celebrities began openly embracing Ozempic on social media in 2022 as a way to lose weight, demand overwhelmed supply. There’s no specific antidote for a semaglutide overdose.
Note: The money behind the makers of weight-loss drugs is staggering, with the economic value of Wegovy's Novo Nordisk soaring to over $420 billionexceeding the entire GDP of Denmark, its home country. Read more on the significant adverse effects associated with these drugs. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.
Karen McCormack, a retired Environmental Protection Agency (EPA) scientist who spent 40 years with the agency, told Al Jazeera’s investigative show Fault Lines that she believed the EPA was not fulfilling its mission to protect the public from harmful chemicals. “In the last three decades that I have worked at EPA it has been very rare for a toxic pesticide to be taken off the market,” she told Fault Lines. “Just about every, every new pesticide application that is submitted to the agency is approved, no matter how high the risk.” As the Al Jazeera report notes, paraquat is banned in 58 countries but its use is on the rise in the United States. The Guardian’s Paraquat Papers, published in 2022 in collaboration with the New Lede, exposed years of corporate efforts to cover up paraquat’s links to Parkinson’s disease, mislead the public, challenge published scientific literature and influence the EPA. Dr Deborah Cory-Slechta, a prominent researcher, told Al Jazeera: “There is a very strong and compelling body of evidence based on the epidemiology studies and what we know from animal models of Parkinson’s disease” that paraquat causes changes in the brain that lead to Parkinson’s. As revealed by the Guardian, in 2005 Syngenta worked behind the scenes to keep Cory-Slechta from sitting on an EPA advisory panel, deeming her a threat to paraquat. Company officials wanted to make sure the efforts could not be traced back to Syngenta, the documents showed.
Note: Internal corporate documents reveal how global chemical giant Syngenta secretly influenced scientific research regarding links between its top-selling weedkiller and Parkinson's disease. For more along these lines, see concise summaries of deeply revealing news articles on health and government corruption from reliable major media sources.
A Ninth Circuit panel on Wednesday rolled back the Environmental Protection Agency’s approval of the use of the pesticide streptomycin sulfate on citrus groves to fight citrus disease. The underlying lawsuit was brought by farmworkers and other interest groups, which argued the EPA had greenlit streptomycin sulfate for use on citrus plants without adequately considering potential harms from the chemical. The panel, consisting of U.S. Circuit Judges Ronald Gould and Johnnie Rawlinson ... and Daniel Bress ... partially ruled in favor of the EPA — determining there was substantial evidence for the EPA’s assessment concerning risks which could lead to antibiotic resistance. However, they said, the EPA’s assessment concerning risks to bees and other pollinators was incomplete. In a statement after the ruling, the Center for Biological Diversity, one of the groups involved in the suit, applauded the Ninth Circuit's decision. The rollback of streptomycin approval "is a significant win for public health, farmworker safety and endangered species," [said attorney] Hannah Connor. Streptomycin sulfate is used as an antibiotic to treat serious illnesses but has also found use as a pesticide. The Center for Biological Diversity claims spraying streptomycin on citrus trees to combat citrus greening disease is “highly ineffective” and argues that its use as a pesticide violates the Endangered Species Act because it causes long-term health effects to endangered animals and plants.
If you’ve ever found yourself absentmindedly humming the “oh-oh-oh-Ozempic” jingle, you have David Paton to blame. The singer-songwriter ... co-wrote “Magic” — the 1975 hit for his band Pilot that he reworked and sang for the trendy weight-loss drug’s TV commercials, which play incessantly. “I have heard from doctors about patients not remembering the names of drugs but singing the songs,” a former product manager for drug companies that include Merck and Pfizer, [said]. It can cost billions of dollars to develop a pharmaceutical, so promoting it is essential. And that all starts with the name. “We try to craft a name that [has] five to nine letters and two to four syllables.” But it even comes down to the exact letters. “Let’s say there is an oral drug instead of an injectable, we’ll explore something that sounds liquidy or has an O in it,” Fernando Fernandez, managing director of BX: Brand Experience Design Group, [said]. “If we expect a product to have an extra level of efficacy, we might put an X in the name.” Consumers like taking drugs with the letter Z, which may have played a role in the naming of Ozempic and Zepbound. According to the Canadian Medical Journal, the letters X, Y and Z all impart a “high tech, sciency” [sic] feeling to drugs such as the sleeping medication Xanax. “People have hesitancy about taking drugs,” a medical advertising veteran told The Post. “If they don’t have diabetes, they wonder why they are taking a diabetes drug to lose weight. The weight-loss drug has to be called something different, even though it is very close to being the same thing. The name Wegovy is playful and memorable and obviously works.”
Note: The money behind the makers of weight-loss drugs is staggering, while concerns grow about the significant adverse effects of these drugs. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma profiteering from reliable major media sources.
Medical experts and politicians have called for the amount of antidepressants being prescribed to people across the UK to be reduced in an open letter to the government. The letter coincides with the launch of the all-party parliamentary group Beyond Pills, which aims to reduce what it calls the UK healthcare system’s over-reliance on prescription medication. A total of 8.6 million patients in England were prescribed antidepressants in 2022-23, with the amount having almost doubled since 2011. Published in the British Medical Journal ... the letter says: “Rising antidepressant prescribing is not associated with an improvement in mental health outcomes at the population level, which, according to some measures, have worsened as antidepressant prescribing has risen.” The letter goes on to say that reducing the rate of antidepressant prescriptions could be achieved through measures that includes stopping the prescribing of antidepressants for mild conditions, and funding and delivering a national 24-hour prescribed drug withdrawal helpline ... to help those experiencing withdrawal symptoms from prescription medication. [Former chief executive of NHS England, Nigel] Crisp said: “The high rate of prescribing of antidepressants over recent years is a clear example of over-medicalisation, where patients are often prescribed unnecessary and potentially harmful drugs instead of tackling the root causes of their suffering, such as loneliness, poverty or poor housing.
Note: Antidepressants are some of the most commonly prescribed medications, yet their significant risks are often withheld from public debate. For more along these lines, see concise summaries of deeply revealing news articles on health and Big Pharma corruption from reliable major media sources.
In 2010, Purdue Pharma replaced the original version of OxyContin, an extended-release oxycodone pill, with a reformulated product that was much harder to crush for snorting or injection. The reformulation of OxyContin was instead associated with an increase in deaths involving illicit opioids and, ultimately, an overall increase in fatal drug overdoses. Researchers ... found that death rates rose fastest in states where reformulation would have had the biggest impact. A new study by RAND Corporation senior economist David Powell extends those findings by showing that the reformulation of OxyContin also was associated with rising suicides among children and teenagers. The root cause of such perverse effects was the substitution that occurred after the old version of OxyContin was retired. Nonmedical users turned to black-market alternatives that were more dangerous because their potency was highly variable and unpredictable—a hazard that was compounded by the emergence of illicit fentanyl as a heroin booster and substitute. The fallout from the reformulation of OxyContin is one example of a broader tendency: Interventions aimed at reducing the harm caused by substance abuse frequently have the opposite effect. Based on interstate differences in nonmedical use of OxyContin prior to 2010, Powell estimates that "the reformulation of OxyContin can explain 49% of the rise in child suicides."
Note: More than 107,000 people in the United States died due to opioid overdoses in 2021. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.
Drugmaker Novo Nordisk paid U.S. medical professionals at least $25.8 million over a decade in fees and expenses related to its weight-loss drugs [Wegovy and Saxenda], a Reuters analysis found. It concentrated that money on an elite group of obesity specialists who advocate giving its powerful and expensive drugs to tens of millions of Americans. Those payments are part of a campaign to convince U.S. doctors to make Wegovy one of the most widely prescribed drugs in history – and to persuade skeptical insurers to pay for it. Overall, at least 57 U.S. physicians each accepted at least $100,000 from Novo in payments associated with Wegovy or Saxenda. They were an influential group: Forty-one were obesity specialists who run weight-management clinics, work at academic hospitals, write obesity-treatment guidelines or hold top positions at medical societies, according to a Reuters review. "As sales grow, Medicare and the insurance industry come under intense pressure to pay for these hugely expensive drugs,” [Former dean of the US military's medical school Dr. Arthur] Kellermann said. “The end result is that everybody's healthcare costs go up.” U.S. and European regulators are studying whether GLP-1 drugs can cause suicidal thoughts. Reuters reported in September that at least 265 reports have been filed with the FDA since 2010 describing suicidal ideation or behavior in patients taking these drugs. Thirty-six reports described a death by suicide or suspected suicide.
Note: The money behind these obesity drug makers is staggering. The economic value of Novo Nordisk soared to over $420 billion, which exceeds the entire GDP of Denmark, its home country. As Lee Fang reports in this investigative piece on the issue, “The company is growing so fast, bringing in so many American dollars, that the Danish central bank recently devalued its currency to keep it in line with the euro.” For more along these lines, read the growing reports of concerning adverse side effects from these weight-loss drugs.
Nonprofit hospitals have been caught doing some surprising things, given how they are supposed to serve the public good in exchange for being exempt from federal, state and local taxes — exemptions that added up to $28 billion in 2020. Detailed media reports show them hounding poor patients for money, cutting nurse staffing too aggressively and giving preferential treatment to the rich over the poor. Nurses and other workers recently resorted to strikes to improve workplace safety at Kaiser Permanente and the Robert Wood Johnson University Hospital in New Brunswick, N.J. That’s not the end of it. Nonprofit executives have embarked on an acquisition spree, assembling huge systems of hospitals and physician practices to raise prices and increase profits. Ample evidence indicates that the growth of these giant systems makes health care less affordable for patients, families and businesses. Calling these hospitals nonprofits can be confusing. It doesn’t mean they can’t make money. What it means is that they are considered charities by the Internal Revenue Service (as opposed to being owned by investors, like for-profit hospitals). And in return for their tax exemptions, these institutions are supposed to invest the money that would have gone to taxes into their communities by lowering health care costs, providing community health services and free care to those unable to afford it and conducting research.
The recent findings of DNA fragments in the Pfizer and Moderna Covid-19 vaccines has led many to question why the FDA, which is responsible for monitoring the quality and safety of the vaccines, has failed to sound the alarm. For years, the FDA has known about the risk posed by residual DNA in vaccines. Its own guidance to industry states: “Residual DNA might be a risk to your final product because of oncogenic and/or infectivity potential. There are several potential mechanisms by which residual DNA could be oncogenic, including the integration and expression of encoded oncogenes or insertional mutagenesis following DNA integration.” Put simply ... fragments of DNA left over by the manufacturing process can be incorporated into a patient’s own DNA, to potentially cause cancer. A recent preprint paper ... analysed batches of the monovalent and bivalent mRNA vaccines. The authors found “the presence of billions to hundreds of billions of DNA molecules per dose in these vaccines. Using fluorometry all vaccines exceed the guidelines for residual DNA set by FDA and WHO.” For the Pfizer product, the higher the level of DNA fragments found in the vaccine, the higher the rate of serious adverse events. Pfizer’s vaccine used in the clinical trials (PROCESS 1) was manufactured differently to the vaccine that was injected into the wider population (PROCESS 2). This switch from PROCESS 1 to PROCESS 2 is what introduced the plasmid DNA impurities.
Note: Watch a fascinating interview with Dr. Ryan Cole, who discusses DNA contamination in the COVID vaccines and its concerning links to the rise in cancers and autoimmune diseases. Although you need a subscription to watch the full video, the full transcript is accessible. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and COVID vaccines from reliable major media sources.
It is against the law to use paraquat in China, Switzerland, the United Kingdom and dozens of other countries. Many countries have banned the herbicide due to its extreme toxicity, while others have expressed concerns over the possible risk for Parkinson's disease. Yet the herbicide, manufactured by a Swiss company that is owned by the Chinese state, is still widely used throughout the United States in part because it is a highly effective way to kill weeds. The company, Syngenta, says that paraquat, which it produces under the name Gramoxone, "is safe for its intended and labelled use." Clayton Tucholke, who used Gramoxone for years on his farm in LaBolt, South Dakota, and has since been diagnosed with Parkinson's disease, says otherwise. "It should have been pulled, I think, you know, so it didn't happen to somebody else," Tucholke told ABC News. The Tucholkes are among the more than 4,000 Americans who have filed lawsuits as part of a multi-district litigation against Syngenta, which currently manufactures Gramoxone, and Chevron, which distributed it in the U.S. from 1966 until 1986. Although Syngenta and Chevron told ABC News that there is no scientific evidence that supports a causal link between paraquat and Parkinson's disease, the Tucholkes and other plaintiffs allege that such a link exists, arguing that Syngenta and Chevron knew or should have known that the herbicide could "cause severe neurological injuries."
Note: Internal corporate documents reveal how global chemical giant Syngenta secretly influenced scientific research regarding links between its top-selling weedkiller and Parkinson's disease. For more along these lines, see concise summaries of deeply revealing news articles on health and food system corruption from reliable major media sources.
Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.